NCR as a biomarker for nutritional status and inflammation in predicting outcomes in patients with cancer cachexia: a prospective, multicenter study
Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospect...
Saved in:
Published in | BMC cancer Vol. 25; no. 1; pp. 539 - 11 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
25.03.2025
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.
This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.
Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.
The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. |
---|---|
AbstractList | Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.BACKGROUNDSystemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.METHODSThis prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.RESULTSAmong the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.CONCLUSIONThe NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. BackgroundSystemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.MethodsThis prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.ResultsAmong the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.ConclusionThe NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. Methods This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Results Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. Conclusion The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. Keywords: NCR, Systemic inflammation, Malnutrition, Cancer cachexia, Overall survival Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. Abstract Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. Methods This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Results Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. Conclusion The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. |
ArticleNumber | 539 |
Audience | Academic |
Author | Deng, Li Xie, Hailun Liu, Tong Shi, Han-Ping Li, Shuqun Lin, Shiqi Liu, ChengAn Li, Xiangrui Liu, Xiaoyue Zhao, Hong |
Author_xml | – sequence: 1 givenname: Xiangrui surname: Li fullname: Li, Xiangrui – sequence: 2 givenname: Li surname: Deng fullname: Deng, Li – sequence: 3 givenname: Hailun surname: Xie fullname: Xie, Hailun – sequence: 4 givenname: Shuqun surname: Li fullname: Li, Shuqun – sequence: 5 givenname: Hong surname: Zhao fullname: Zhao, Hong – sequence: 6 givenname: Tong surname: Liu fullname: Liu, Tong – sequence: 7 givenname: Xiaoyue surname: Liu fullname: Liu, Xiaoyue – sequence: 8 givenname: Shiqi surname: Lin fullname: Lin, Shiqi – sequence: 9 givenname: ChengAn surname: Liu fullname: Liu, ChengAn – sequence: 10 givenname: Han-Ping surname: Shi fullname: Shi, Han-Ping |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40133874$$D View this record in MEDLINE/PubMed |
BookMark | eNptk9tu1DAQhiNURA_wAlwgS0gIJFJs52CHG1StOKxUgVTg2po4zq5LEm9tp7TvwQMz2S1lg5AlH8bf_LbHM8fJweAGkyRPGT1lTJZvAuNSFinlRcqyilUpe5AcsVywlOdUHOzND5PjEC4pZUJS-Sg5zCnLMinyo-TX58UFgUCA1Nb14H8YT1rnyTBGb6N1A3QkRIgjIkND7NB20Pcw7eCCbLxprI52WBE3Ru16E7ZmBMwQA_lp45poGDTKatBrc2PhLR628S5sDDpem9ekH7toNfIIhTg2t4-Thy10wTy5G0-S7x_ef1t8Ss-_fFwuzs5TXUge0zpnjdAMGm6o1hzKLBdUS8hLoLytTEN13dai1pkWmpuaV5yCrnldMFYYSrOTZLnTbRxcqo23GIBb5cCqrcH5lQKPV-uMmgJW0spUlcxRv4VaMFEWUvNCs9o0qPVup7UZ694003M8dDPR-c5g12rlrhVjVZaXskKFl3cK3l2NJkTV26BN18Fg3BhUxiTLSknphD7_B710o8e_2lKiyCsh5V9qBfgC_DqHB-tJVJ3JjBeI5Qyp0_9Q2BrTW40Z11q0zxxezRyQieYmrmAMQS2_XszZF3vs2kAX18F145Q_YQ4-2w_ffdz-ZCoCfAdoTJ3gTXuPMKqmclC7clBYDmpbDtj_BgXR_K0 |
Cites_doi | 10.1016/j.immuni.2019.06.025 10.1038/sj.bjc.6605578 10.1038/nature07205 10.1002/jcsm.12761 10.1186/1475-2891-11-27 10.1016/j.clnu.2016.09.004 10.1002/jcsm.13358 10.1016/S1470-2045(14)70263-3 10.1016/j.clnu.2019.12.024 10.3390/diagnostics13010116 10.1038/nrdp.2017.105 10.1016/j.esmoop.2021.100092 10.1016/S1470-2045(10)70218-7 10.1054/bjoc.2001.2046 10.1016/j.clnu.2017.06.017 10.1186/s13045-023-01454-0 10.1186/s12885-023-11590-y 10.1016/j.clnu.2022.04.019 10.1016/j.tem.2012.10.006 10.1016/j.clnu.2020.10.050 10.1002/jcsm.12528 10.1200/JCO.2008.18.9068 10.1093/ajcn/83.6.1345 10.1097/PN1099.0000000000000008 10.1200/JCO.2012.45.2722 10.1093/annonc/mdy004 10.1002/jpen.2407 10.1016/S0149-2918(05)80001-3 10.1038/ni.3754 10.1038/s41571-023-00734-5 |
ContentType | Journal Article |
Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12885-025-13919-1 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Acceso a contenido Full Text - Doaj |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2407 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_0133609e998446afab717658c25c1bed PMC11934689 A832554941 40133874 10_1186_s12885_025_13919_1 |
Genre | Multicenter Study Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: National Key Research and Development Program grantid: No. 2022YFC2009600 |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c582t-b41d7c1ad2e0cc2a63470c8a46a02f9ed0cbfb7bc3c7c2eb2920acb2b5115e003 |
IEDL.DBID | M48 |
ISSN | 1471-2407 |
IngestDate | Wed Aug 27 01:27:28 EDT 2025 Thu Aug 21 18:39:58 EDT 2025 Fri Jul 11 18:57:24 EDT 2025 Fri Jul 25 21:02:05 EDT 2025 Tue Jun 17 21:58:35 EDT 2025 Tue Jun 10 20:59:14 EDT 2025 Fri Jun 27 05:13:02 EDT 2025 Thu May 22 21:23:35 EDT 2025 Thu May 22 05:05:16 EDT 2025 Tue Jul 01 05:20:27 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Cancer cachexia Malnutrition NCR Overall survival Systemic inflammation |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c582t-b41d7c1ad2e0cc2a63470c8a46a02f9ed0cbfb7bc3c7c2eb2920acb2b5115e003 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/3187549788?pq-origsite=%requestingapplication% |
PMID | 40133874 |
PQID | 3187549788 |
PQPubID | 44074 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0133609e998446afab717658c25c1bed pubmedcentral_primary_oai_pubmedcentral_nih_gov_11934689 proquest_miscellaneous_3181368009 proquest_journals_3187549788 gale_infotracmisc_A832554941 gale_infotracacademiconefile_A832554941 gale_incontextgauss_ISR_A832554941 gale_healthsolutions_A832554941 pubmed_primary_40133874 crossref_primary_10_1186_s12885_025_13919_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-03-25 |
PublicationDateYYYYMMDD | 2025-03-25 |
PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-25 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC cancer |
PublicationTitleAlternate | BMC Cancer |
PublicationYear | 2025 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 13919_CR4 CG Lis (13919_CR31) 2012; 11 K Nordin (13919_CR16) 2001; 85 13919_CR2 RD Dolan (13919_CR30) 2020; 39 X Zhang (13919_CR22) 2023; 47 FR Greten (13919_CR17) 2019; 51 WD Dewys (13919_CR10) 1980; 69 L Martin (13919_CR11) 2013; 31 13919_CR32 KC Fearon (13919_CR29) 2006; 83 13919_CR14 T Cederholm (13919_CR24) 2017; 36 T Setiawan (13919_CR6) 2023; 16 JM Argiles (13919_CR3) 2023; 20 J Arends (13919_CR25) 2017; 36 BL Pierce (13919_CR21) 2009; 27 L Han (13919_CR5) 2024; 3 Q Zhang (13919_CR7) 2021; 12 GS de Castro (13919_CR20) 2021; 40 HL Xie (13919_CR12) 2021; 11 GT Ruan (13919_CR9) 2023; 14 M Tsoli (13919_CR26) 2013; 24 L Zitvogel (13919_CR27) 2017; 18 K Fearon (13919_CR1) 2011; 12 E Dell'Aquila (13919_CR15) 2018; 29 A Mantovani (13919_CR18) 2008; 454 13919_CR28 SI Go (13919_CR13) 2023; 23 M Pressoir (13919_CR23) 2010; 102 H Xie (13919_CR8) 2022; 41 CI Diakos (13919_CR19) 2014; 15 |
References_xml | – volume: 51 start-page: 27 issue: 1 year: 2019 ident: 13919_CR17 publication-title: Immunity doi: 10.1016/j.immuni.2019.06.025 – volume: 102 start-page: 966 issue: 6 year: 2010 ident: 13919_CR23 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605578 – volume: 454 start-page: 436 issue: 7203 year: 2008 ident: 13919_CR18 publication-title: Nature doi: 10.1038/nature07205 – volume: 12 start-page: 1466 issue: 6 year: 2021 ident: 13919_CR7 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12761 – volume: 11 start-page: 27 year: 2012 ident: 13919_CR31 publication-title: Nutr J doi: 10.1186/1475-2891-11-27 – volume: 36 start-page: 49 issue: 1 year: 2017 ident: 13919_CR24 publication-title: Clin Nutr doi: 10.1016/j.clnu.2016.09.004 – volume: 14 start-page: 2813 issue: 6 year: 2023 ident: 13919_CR9 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.13358 – volume: 15 start-page: e493 issue: 11 year: 2014 ident: 13919_CR19 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70263-3 – volume: 39 start-page: 2889 issue: 9 year: 2020 ident: 13919_CR30 publication-title: Clin Nutr doi: 10.1016/j.clnu.2019.12.024 – ident: 13919_CR14 doi: 10.3390/diagnostics13010116 – ident: 13919_CR2 doi: 10.1038/nrdp.2017.105 – ident: 13919_CR28 doi: 10.1016/j.esmoop.2021.100092 – volume: 3 issue: 1 year: 2024 ident: 13919_CR5 publication-title: Precision Nutrition – volume: 12 start-page: 489 issue: 5 year: 2011 ident: 13919_CR1 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70218-7 – volume: 85 start-page: 1265 issue: 9 year: 2001 ident: 13919_CR16 publication-title: Br J Cancer doi: 10.1054/bjoc.2001.2046 – volume: 36 start-page: 1187 issue: 5 year: 2017 ident: 13919_CR25 publication-title: Clin Nutr doi: 10.1016/j.clnu.2017.06.017 – volume: 16 start-page: 54 issue: 1 year: 2023 ident: 13919_CR6 publication-title: J Hematol Oncol doi: 10.1186/s13045-023-01454-0 – volume: 23 start-page: 1071 issue: 1 year: 2023 ident: 13919_CR13 publication-title: BMC Cancer doi: 10.1186/s12885-023-11590-y – volume: 41 start-page: 1236 issue: 6 year: 2022 ident: 13919_CR8 publication-title: Clin Nutr doi: 10.1016/j.clnu.2022.04.019 – volume: 24 start-page: 174 issue: 4 year: 2013 ident: 13919_CR26 publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2012.10.006 – volume: 40 start-page: 2443 issue: 4 year: 2021 ident: 13919_CR20 publication-title: Clin Nutr doi: 10.1016/j.clnu.2020.10.050 – ident: 13919_CR32 doi: 10.1002/jcsm.12528 – volume: 27 start-page: 3437 issue: 21 year: 2009 ident: 13919_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.9068 – volume: 83 start-page: 1345 issue: 6 year: 2006 ident: 13919_CR29 publication-title: Am J Clin Nutr. doi: 10.1093/ajcn/83.6.1345 – ident: 13919_CR4 doi: 10.1097/PN1099.0000000000000008 – volume: 31 start-page: 1539 issue: 12 year: 2013 ident: 13919_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.2722 – volume: 29 start-page: 924 issue: 4 year: 2018 ident: 13919_CR15 publication-title: Ann Oncol doi: 10.1093/annonc/mdy004 – volume: 47 start-page: 109 issue: 1 year: 2023 ident: 13919_CR22 publication-title: JPEN J Parenter Enteral Nutr doi: 10.1002/jpen.2407 – volume: 69 start-page: 491 issue: 4 year: 1980 ident: 13919_CR10 publication-title: Am J Med doi: 10.1016/S0149-2918(05)80001-3 – volume: 18 start-page: 843 issue: 8 year: 2017 ident: 13919_CR27 publication-title: Nat Immunol doi: 10.1038/ni.3754 – volume: 20 start-page: 250 issue: 4 year: 2023 ident: 13919_CR3 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-023-00734-5 – volume: 11 year: 2021 ident: 13919_CR12 publication-title: Front Oncol |
SSID | ssj0017808 |
Score | 2.4434352 |
Snippet | Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the... Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate... BackgroundSystemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate... Abstract Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 539 |
SubjectTerms | Aged Albumin Analysis Biological markers Biomarkers Biomarkers - blood Blood Body Mass Index Breast C-Reactive Protein - analysis C-Reactive Protein - metabolism Cachexia Cachexia - blood Cachexia - diagnosis Cachexia - etiology Cachexia - mortality Cancer Cancer cachexia Cancer patients Cancer therapies Care and treatment Cervical cancer China - epidemiology Constipation Cytokines Development and progression Diagnosis Diarrhea Dyspnea Female Global health Humans Inflammation Inflammation - blood Insomnia Liver Lung cancer Lymphocytes Male Malnutrition Medical diagnosis Medical prognosis Middle Aged Mortality Musculoskeletal system NCR Neoplasms - complications Neoplasms - mortality Nutritional Status Oncology, Experimental Overall survival Patient outcomes Patients Prognosis Prospective Studies Proteins Quality of life Questionnaires Risk factors Survival analysis Systemic inflammation Tumor necrosis factor-TNF |
SummonAdditionalLinks | – databaseName: Acceso a contenido Full Text - Doaj dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4ptAAYOQOEBUx_mww61UVAWpPRQq9WbZjgO9ZKvNRuKH9Af3jZOsNuLAhdNq48kmmXkev9nMjBl7D5dfVUWJMLV2bVq4RqVO2Ta1IletrV0WBBU4n55VJxfF98vycmerL8oJG9sDj4o7AEXJK1EHhAWIXGxrHQIQLJtelj5zoSHvizVvDqam9wdKCz2XyOjqoIcX1lSJXKZgPFmdZotlKHbr_9sn7yxKy4TJnRXo-AG7P1FHfjje8kN2J3SP2N3T6eX4Y3ZzdnTObc8tp5p6SrtZc1BS3s0N93Ey1Q8NEOkaDmgBDWPlIr7w6zX9EmVB89WwARBDHw-PjVd7Tv_Yck8gWeMDtv5zZT_jYniOuVzzE4_5iXT_EIqda5-wi-OvP49O0mnThdSXWm5SV2SN8pltZBDeS1vlhRJeW-heyLYOjfCudcr53CsvEZfXUljvpANzKwN8xFO216268JxxDfMHhC-gXLLQVlvQhdbpzOdKtFLVCfs428Bcj701TIxJdGVGixlYzESLmSxhX8hMW0nqix0PAC1mQov5F1oS9oaMbMYi0-3sNodwbCBWdYHLvIsS1Bujo-SbX3boe_Ptx_lC6MMk1K4ACCh9rGXAc1M7rYXk_kISk9cvh2e0mcl59AZuVpW0859O2NvtMJ1JCXFdWA1RJssrsH1o8dkIzq1mKGTOtSoSphewXahuOdJd_Y6txTPw-aLS9Yv_oeyX7J6kKSfyVJb7bG-zHsIrULiNex1n6y0B6kR- priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4t2FAgYhcYCojvOwwwWViqogtYdCpd4s23FKL8my2ZX4IfxgvnGSpRESp1XiySaZl79xZsaMvYHLL8u8QJhauSbJXa0Sp2yTWJGpxlYuDYIKnE9Oy-Pz_OtFcTEuuPVjWuXkE6OjrjtPa-T70D1V0HZo-uPyZ0K7RtHX1XELjZvsFrUuo5QudbENuFKlhZ4KZXS538MXa6pHLhLgnrRK0tlkFHv2_-uZr01N87TJa_PQ0T12dwSQ_GCQ-H12I7QP2O2T8RP5Q_b79PCM255bTpX1lHyz4gCmvJ3a7uNiqiLagKStORQMOjHUL-KAL1f0T5QLzbvNGqwJfTw9tF_tOa3bck-qssIPJP7ryn7AzfAeU9Hmex6zFOn5QRT71z5i50efvx8eJ-PWC4kvtFwnLk9r5VNbyyC8l7bMciW8tnlphWyqUAvvGqecz7zyEtF5JYX1TjrgtyLAUzxmO23Xhl3GNZQgIIgB8JK5ttoCNDROpz5TopGqWrB3kwzMcuiwYWJkokszSMxAYiZKzKQL9onEtKWk7tjxRLe6NKOxGcDarBRVQCiJaNc21iFoBdTysvCpC_WCvSQhm6HUdGvj5gDuDfCqynGb15GCOmS0lIJzaTd9b758O5sRvR2Jmg4KAaYPFQ14b2qqNaPcm1HChP18eNI2M7qQ3vxV-AV7tR2mKyktrg3dJtKkWQnMDy4-GZRzyxkKnDOt8gXTM7WdsW4-0l79iA3GYUtZXurq6f-f6xm7I8mYRJbIYo_trFeb8BwQbe1eRDv8A7R0PME priority: 102 providerName: ProQuest |
Title | NCR as a biomarker for nutritional status and inflammation in predicting outcomes in patients with cancer cachexia: a prospective, multicenter study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40133874 https://www.proquest.com/docview/3187549788 https://www.proquest.com/docview/3181368009 https://pubmed.ncbi.nlm.nih.gov/PMC11934689 https://doaj.org/article/0133609e998446afab717658c25c1bed |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLbGJiFeEHcKoxiExAMEEudiBwmhddo0kFqhQqWKF8t2nDEJpSNppfE_-MF8dpKyiD3w0qrxSdycm8-XnHNMyAu4_CxLUsDUXJdBogseaK7KQIUxL1WuIxu6AufpLDtZJJ-W6XKH9NsddQxsroR2bj-pRf3jzcXPXx9g8O-9wYvsbQMfK1ydcRognonyAGhoDysTd4Y6Tf6-VeDC71AXwSG7twq8L6K58hqDhcr38__Xa19atoYplZfWqONb5GYXXNKDVhtukx1b3SHXp93r87vk9-xwTlVDFXVV9y4xp6YIWmnVt-THya7CaAOSqqBgB_SlrW3ED3peuyu5PGm62qyhqrbxh9vWrA11z3SpcWpU4wvacHGm3mEy3Edf0Pma-gxG9_9B5Hvb3iOL46OvhydBty1DYFLB1oFOooKbSBXMhsYwlcUJD41QSaZCVua2CI0uNdcmNtwwIPechcpophHbpRZe5D7ZrVaVfUiogIJYABwEZSwRSigEFKUWkYl5WDKej8irXgbyvO2-IT1qEZlsJSYhMeklJqMRmTgxbSld52x_YFWfys4QJULeOAtzC5gJJKxKpQFoEYYZlppI22JEnjohy7YMdWv_8gCuD6FXnmCa557Cdc-oXHrOqdo0jfz4ZT4getkRlSsoBJjeVjvgvl3DrQHl_oAS5m2Gw722yd46JBwxT93egGJEnm2H3ZkuZa6yq42nieIMeABcfNAq55YzDlTHgicjIgZqO2DdcKQ6--6bj0eI-JNM5I_-Y-LH5AZzFhXGAUv3ye663tgniOHWekyu8SUfk73J0ezzfOyfhIy9seJzPvn2B5ZGSDE |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVgIuiH8WCjUIxIFGTRwndpAQakurXdpdodJKvRnbcUovybLZFfAePAfPyIyTLI2QuPW02njy5_k8ni-eGRPyEkx-mvIEaGpmioCbXARG6CLQYSwKnZnIhZjgPJmmo1P-8Sw5WyO_u1wYDKvsbKI31Hll8Rv5NmBPJLgdmnw_-xbgrlG4utptodHA4tD9_A6UrX43_gD6fcXYwf7J3ihodxUIbCLZIjA8yoWNdM5caC3TacxFaKXmqQ5Zkbk8tKYwwtjYCsuAeGYs1NYwA65J4mAQwHWvkXUeA5UZkPXd_emn49W6hZCh7FJzZLpdg_WXmAGdBOBpRVkQ9aY_v0vAv3PBpcmwH6h5aeY7uE1utS4r3WkwdoesufIuuT5pF-XvkV_TvWOqa6op5vJjuM-cgitMy67QP5yMeUtLEClzCpAGFDYZk_CHzuZ4JYy-ptVyAcpwtT_cFHytKX4pphbBOYcfwNiPC_0Wbgbv0aWJblEfF4nPD0K-Yu59cnolanlABmVVukeESoCdA9oErh7jUksNbkphZGRjERZMZEPyptOBmjU1PZTnQjJVjcYUaEx5jaloSHZRTStJrMftD1Tzc9UObwWONOAhc0BegV_rQhugyeDcWZbYyLh8SDZRyapJbl1ZFbUDBhUcuozDbV54CazJUWLQz7le1rUafz7uCb1uhYoKAAGd3uRQwHtjGa-e5EZPEoyG7Td3aFOt0arV3yE2JM9XzXgmBuKVrlp6mShOgWVALz5swLnqGaTqsRR8SGQPtr2u67eUF199SfMIeARPZfb4_8-1SW6MTiZH6mg8PXxCbjIcWGEcsGSDDBbzpXsKDuLCPGtHJSVfrtoQ_AHP63yW |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NCR+as+a+biomarker+for+nutritional+status+and+inflammation+in+predicting+outcomes+in+patients+with+cancer+cachexia%3A+a+prospective%2C+multicenter+study&rft.jtitle=BMC+cancer&rft.au=Li%2C+Xiangrui&rft.au=Deng%2C+Li&rft.au=Xie%2C+Hailun&rft.au=Li%2C+Shuqun&rft.date=2025-03-25&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=25&rft.issue=1&rft.spage=539&rft_id=info:doi/10.1186%2Fs12885-025-13919-1&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |